Repopulation of A2-NLV–specific CD8⁺ T cells after allogeneic, T-cell–depleted SCT.

In each panel, the horizontal line indicates the 95th percentile of 29 healthy CMV-seropositive (SCT) HLA-A2⁺ individuals. Among CMV-seropositive recipients with CMV antigenemia (C,D), differences in A2-NLV–specific CD8⁺ T-cell counts between patients without and with CMV disease were significant between 2 and 9 months after SCT (P values between .001 and .05 using Wilcoxon test). During that period, differences in total CD8⁺ T-cell counts between patients without and with CMV disease were not significant. See further the legend to Figure 3.